The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (interstitial lung disease/ILD)

Publications

Dimeas IE, Perlepe G, Kirgou P, McCarthy C, Daniil Z

A case of breathlessness and unexpected antibodies: stating the obvious.

Breathe (Sheffield, England) 2026 Apr;22 — 2026 Apr — 250358

Meira Dias O, Guedes Baldi B, Nathan Costa A, Katsuyuki Shinjo S, Miossi R, Adib Kairalla R

Interstitial lung disease with statin-associated necrotizing autoimmune myopathy responding to rituximab.

Archivos de bronconeumologia 2016 Jul;52;395-7 — 2016 Jul — 395-7

Takakura A, Kubota M, Otani S, Katono K, Yamamoto M, Masuda N

[A case of valsartan-induced pneumonitis with marked elevation of serum KL-6].

Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 2011 Jul;49;523-7 — 2011 Jul — 523-7

Fernández AB, Karas RH, Alsheikh-Ali AA, Thompson PD

Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports.

Chest 2008 Oct;134;824-30 — 2008 Oct — 824-30

Walker T, McCaffery J, Steinfort C

Potential link between HMG-CoA reductase inhibitor (statin) use and interstitial lung disease.

The Medical journal of Australia 2007 Jan 15;186;91-4 — 2007 Jan 15 — 91-4